These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38937437)

  • 1. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug.
    Liu Q; Lu Y; Cai C; Huang Y; Zhou L; Guan Y; Fu S; Lin Y; Yan H; Zhang Z; Li X; Yang X; Yang H; Guo H; Lan K; Chen Y; Hou SC; Xiong Y
    Cell Death Dis; 2024 Jun; 15(6):458. PubMed ID: 38937437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
    Sluchanko NN; Shcheblyakov DV; Varfolomeeva LA; Favorskaya IA; Dolzhikova IV; Korobkova AI; Alekseeva IA; Esmagambetov IB; Derkaev AA; Prokofiev VV; Zorkov ID; Logunov DY; Gintsburg AL; Popov VO; Boyko KM
    Biochemistry (Mosc); 2024 Jul; 89(7):1260-1272. PubMed ID: 39218023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
    Esparza TJ; Martin NP; Anderson GP; Goldman ER; Brody DL
    Sci Rep; 2020 Dec; 10(1):22370. PubMed ID: 33353972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of
    Ye G; Gallant J; Zheng J; Massey C; Shi K; Tai W; Odle A; Vickers M; Shang J; Wan Y; Du L; Aihara H; Perlman S; LeBeau A; Li F
    Elife; 2021 Aug; 10():. PubMed ID: 34338634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
    Valenzuela Nieto G; Jara R; Watterson D; Modhiran N; Amarilla AA; Himelreichs J; Khromykh AA; Salinas-Rebolledo C; Pinto T; Cheuquemilla Y; Margolles Y; López González Del Rey N; Miranda-Chacon Z; Cuevas A; Berking A; Deride C; González-Moraga S; Mancilla H; Maturana D; Langer A; Toledo JP; Müller A; Uberti B; Krall P; Ehrenfeld P; Blesa J; Chana-Cuevas P; Rehren G; Schwefel D; Fernandez LÁ; Rojas-Fernandez A
    Sci Rep; 2021 Feb; 11(1):3318. PubMed ID: 33558635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
    Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
    Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
    Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
    Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
    Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2.
    Li T; Zhou B; Li Y; Huang S; Luo Z; Zhou Y; Lai Y; Gautam A; Bourgeau S; Wang S; Bao J; Tan J; Lavillette D; Li D
    Int J Biol Macromol; 2022 Jun; 209(Pt A):1379-1388. PubMed ID: 35460753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
    Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
    Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
    Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
    Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L
    Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
    Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
    Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.